IQwave™ D-EECT comes out better than the ESOPE protocol in its first publication
A Case study performed in Chennai in India under the leadership of Dr. Kalavathy as leading physician, Prof Emeritus Bertil Persson as Corresponding author was published in “Trends in Cancer Research” in its 13th editions 2018, a scientific cancer paper in India.
In the conclusions of this publication the author says:
”In all of the evaluable tumours the objective responses were found to be 100%, with complete remissions at 18%, and partial remissions at 82%. No progressive disease was recorded, and the average weighted response became 45 ±17%.”
Even if the populations was limited to 23 patients in this case report, we are happy to reach these results on tumours that has shown not to respond to radiations or traditional chemotherapy. That 18% of the tumours was completely gone and the progression of the disease was zero after D-EECT treatments show to potential of IQwave™, says Mohan Frick CEO at ChemoTech.
The complete research paper is to be found on the following link:
http://www.researchtrends.net/tia/article_pdf.asp?in=0&vn=13&tid=57&aid=6173
For more information, please contact:
Mohan Frick, CEO
+46 (0)10-218 93 00
This information is such information which Scandinavian ChemoTech AB (publ) are obligated to make public according to EU’s market abuse regulation. The information was submitted by the agency of above stated contact person, to be made public on Monday the 10th of September 2018 at 08.30 (CET).
Scandinavian ChemoTech AB (publ)
ChemoTech is a young and dynamic life science company that possesses a great medical expertise and technical knowledge. Our latest launch of IQwave™ is an innovation within electrochemotherapy, that is adapted for the treatment of different types of tumors. ChemoTech strives to contribute to a more accessible cancer care. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North in Stockholm and Västra Hamnen Corporate Finance AB is the company's Certified Adviser. The company is headquartered in Malmö, in the midst of the medical technology expansionary Öresund region.